PMID- 37652498
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231102
IS  - 1791-7549 (Electronic)
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 37
IP  - 5
DP  - 2023 Sep-Oct
TI  - In Vitro Carbon Ion Beam and Gemcitabine Chemoradiation in a Mucoepidermoid 
      Carcinoma Cell Line.
PG  - 1951-1959
LID - 10.21873/invivo.13291 [doi]
AB  - BACKGROUND/AIM: To determine the interaction of gemcitabine in chemoradiotherapy 
      with heavy carbon ions in vitro in a mucoepidermoid carcinoma (MEC) cell line. 
      MATERIALS AND METHODS: The human lymphatic MEC metastasis cell line NCI-H292 was 
      used. The cells were treated with photons, carbon ions, and gemcitabine. Survival 
      fractions (SF), apoptosis, and cell cycle progression were analyzed. A paired 
      two-sided t-test was used. Significance was defined as p<0.05. RESULTS: Cell 
      proliferation assays showed a significant reduction in SF for combined photon 
      chemoradiation versus photons only. The linear-quadratic fits of combined therapy 
      with carbon ion dose of 0 to 2.5 Gy led to reductions of mean 15% in SF. The 
      LD(50) (lethal radiation dose required to reduce cell survival by 50%) for carbon 
      ions only was 0.7 Gy and for carbon ions with gemcitabine 0.6 Gy. The LD(50) for 
      photons (with gemcitabine) was 2.8 Gy (2.0 Gy) and for carbon ions (with 
      gemcitabine) 0.7 Gy (0.6 Gy), resulting in a relative biological effectiveness at 
      10% cell survival (RBE10) of 3.0 (2.7). Carbon ions and photons reduced S phase 
      and increased G2/M phase cell distribution. Isolated treatment with gemcitabine 
      as well as combination with photons led to prolonged S phase transit, whereas 
      combined treatment with carbon ions led to early accumulation in G2/M phase. A 
      significant increase in the sub-G1 population as a hint of relevant number of 
      apoptotic cells was not observed. CONCLUSION: Gemcitabine showed radiosensitizing 
      effects in combination with photons. The combination of gemcitabine and carbon 
      ions had independent additive effects. Carbon ions only had a RBE10 of 3.0, 
      compared to photons only. The combination of gemcitabine, photon, and carbon ions 
      in patients with MEC seems promising and warrants further investigation.
CI  - Copyright (c) 2023, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Schneider, Thomas
AU  - Schneider T
AD  - Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, 
      Germany.
AD  - Department of Diagnostic and Interventional Radiology, Heidelberg University 
      Hospital, Heidelberg, Germany.
FAU - Zwicker, Felix
AU  - Zwicker F
AD  - Clinical Cooperation Unit E055, German Cancer Research Center (DKFZ), Heidelberg, 
      Germany.
FAU - Huber, Peter Ernst
AU  - Huber PE
AD  - Clinical Cooperation Unit E055, German Cancer Research Center (DKFZ), Heidelberg, 
      Germany.
FAU - Debus, Jurgen
AU  - Debus J
AD  - Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, 
      Germany.
AD  - Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.
AD  - National Center for Radiation Research in Oncology (NCRO), Heidelberg Institute 
      for Radiation Oncology (HIRO), Heidelberg, Germany.
AD  - DKTK Site Heidelberg, German Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Hauswald, Henrik
AU  - Hauswald H
AD  - Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, 
      Germany; hausw@gmx.de.
AD  - Clinical Cooperation Unit E055, German Cancer Research Center (DKFZ), Heidelberg, 
      Germany.
AD  - RNS Gemeinschaftspraxis, Wiesbaden, Germany.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - 0 (Gemcitabine)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 7440-44-0 (Carbon)
RN  - 0 (Ions)
SB  - IM
MH  - Humans
MH  - Gemcitabine
MH  - Deoxycytidine/pharmacology
MH  - *Carcinoma, Mucoepidermoid/drug therapy
MH  - Cell Line, Tumor
MH  - *Heavy Ion Radiotherapy/methods
MH  - Chemoradiotherapy/methods
MH  - Photons/therapeutic use
MH  - Carbon/therapeutic use
MH  - Ions
PMC - PMC10500520
OTO - NOTNLM
OT  - Mucoepidermoid carcinoma
OT  - carbon ion beam therapy
OT  - chemoradiation
OT  - head and neck
OT  - in vitro
OT  - ion beam therapy
OT  - particle beam therapy
OT  - radiotherapy
COIS- The Authors declare that they have no competing interests in relation to this 
      study.
EDAT- 2023/09/01 00:42
MHDA- 2023/09/01 00:43
PMCR- 2023/09/03
CRDT- 2023/08/31 20:37
PHST- 2023/05/22 00:00 [received]
PHST- 2023/06/16 00:00 [revised]
PHST- 2023/06/19 00:00 [accepted]
PHST- 2023/09/01 00:43 [medline]
PHST- 2023/09/01 00:42 [pubmed]
PHST- 2023/08/31 20:37 [entrez]
PHST- 2023/09/03 00:00 [pmc-release]
AID - 37/5/1951 [pii]
AID - 10.21873/invivo.13291 [doi]
PST - ppublish
SO  - In Vivo. 2023 Sep-Oct;37(5):1951-1959. doi: 10.21873/invivo.13291.